TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23104146
Drug: Intravenous ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ondansetron 8 mg
Study: 21606305
Drug: Hydroxyurea therapy
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea therapy (part of the BABY HUG trial)
Study: 7685442
Drug: Losartan >
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan > 10 mg
Study: 2444780
Drug: Nifedipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (mean dose, 70 mg/day)
Study: 2444780
Drug: Nitroglycerin patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin patches (mean dose, 16 cm/day)
Study: 2444780
Drug: Control period
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control period (no other antianginal treatment)
Study: 29764853
Drug: CC-486 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 monotherapy (300 mg, every day, days 1-14/21)
Study: 29764853
Drug: CC-486 in
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 in combination with carboplatin (300 mg, every day, days 1-14/21)
Study: 29764853
Drug: CC-486 in
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 in combination with nab-paclitaxel (200 mg, every day, days 1-14/21)
Study: 29764853
Drug: CC-486 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 (various doses)
Study: 26915749
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (n=109)
Study: 21592681
Drug: Sertraline (100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (100mg daily)
Study: 9262265
Drug: Bolus injection
Normalized name: SET,INFUSION,BOLUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus injection of FSH (450 IU i.m.)
Study: 8365747
Drug: 1.5 x
Normalized name: lisocabtagene maraleucel 1.5 x 10exp6 to 70 x 10exp6 cell/mL INTRAVEN VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 x 10(6) units of streptokinase (SK) in 200 ml of normal saline
Study: 8365747
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of normal saline alone (control)
Study: 27595715
Drug: Single-session root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-session root canal treatment (GSS)
Study: 27595715
Drug: Two-session root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-session root canal treatment with calcium hydroxide intracanal medication (GTS)
Study: 20628004
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea (6 cups daily for 3 to 6 weeks)
Study: 16595780
Drug: Low-dose isotretinoin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose isotretinoin (30 mg/day)
Study: 7171415
Drug: Methadone 10
Normalized name: normethadone 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone 10 mg i.v. (acute administration)
Study: 25849254
Drug: Primary tumor
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary tumor resection followed by systemic chemotherapy
Study: 31417958
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy alone
Study: 24021606
Drug: One specific
Normalized name: Fruit cone specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: One specific physical treatment device using a biorhythmically defined stimulus for vasomotion
Study: 24021606
Drug: Two other
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two other physical treatment devices
Study: 24021606
Drug: Three other
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three other physical treatment devices
Study: 20070133
Drug: Stepped Collaborative
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Stepped Collaborative Care (CC)
Study: 20070133
Drug: CC (Control)
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (Control)
Study: 3129806
Drug: Lithium preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium preparations (lithium carbonate, lithium oxybutyrate)
Study: 3129806
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and standard antiulcerative therapy
Study: 23207186
Drug: YGD (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: YGD (3 tablets)
Study: 18629524
Drug: FREMS therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FREMS therapy
Study: 16582130
Drug: Misoprostol 800
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol 800 mcg vaginally on study day 1, with a repeat dose if indicated on day 3.
Study: 8858462
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg i.v. at 8 hourly intervals (group 1 and 2)
Study: 8858462
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg i.v. at 12 hourly intervals (group 3)
Study: 8858462
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg i.v. at 12 hourly intervals (group 4)
Study: 1512337
Drug: Captopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (4 days of therapy)
Study: 30328569
Drug: Shenzhu Guanxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenzhu Guanxin Recipe Granules (SGR) 10 g/day for 12 weeks
Study: 27583882
Drug: Collateral Meridian
Normalized name: sibutramine hydrochloride Oral Capsule [Meridia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collateral Meridian Therapy (CMT)
Study: 22863159
Drug: Combination aliskiren/hydrochlorothiazide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination aliskiren/hydrochlorothiazide (HCT) 150/12.5 mg
Study: 22863159
Drug: Aliskiren 150
Normalized name: aliskiren 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 150 mg (force-titrated to 300/25 mg and 300 mg)
Study: 20582746
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg 0.2% ropivacaine
Study: 20582746
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg 0.2% ropivacaine plus 0.5 mg/kg ketamine
Study: 9813398
Drug: Rifaximin 200
Normalized name: rifAXIMin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 200 mg t.i.d.
Study: 9813398
Drug: Rifaximin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin (all doses)
Study: 26121788
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration therapy (ORT) group, allowed to drink clear liquids until 2 hours before anesthesia induction
Study: 23241727
Drug: 400 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 µg of misoprostol orally 12 hours before the procedure
Study: 21939942
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus glycoprotein IIb/IIIa inhibitor (GPI)
Study: 18652102
Drug: Bupivacaine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine (3 ml of isobaric bupivacaine 5 mg/ml)
Study: 18652102
Drug: Ropivacaine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine (3 ml of isobaric ropivacaine 5 mg/ml)
Study: 18652102
Drug: Levobupivacaine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (3 ml of isobaric levobupivacaine 5 mg/ml)
Study: 11163674
Drug: Standard titre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard titre measles vaccine given at age 9 months
Study: 11163674
Drug: Standard titre
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard titre measles vaccine given at age 6 months
Study: 11163674
Drug: Both vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccine groups
Study: 7820191
Drug: Medrogestone (M)
Normalized name: medrogestone
DrugBank: Medrogestone (DB09124)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medrogestone (M) at a dose of 10 mg/day from D4 to D24
Study: 2830642
Drug: Chemotherapy (cisplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin 70 mg/m2 i.v. day one, etoposide 100 mg/m2 i.v. day one, 200 mg/m2 orally days 2 and 3, repeated every third week to a maximum of 4 cycles)
Study: 1385603
Drug: amphetamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: amphetamine (15 mg)
Study: 1385603
Drug: placebo/amphetamine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo/amphetamine (15 mg)
Study: 28954882
Drug: Caffeine 200
Normalized name: caffeine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 200 mg BID for 6-18 months
Study: 28954882
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules for 6-18 months
Study: 28954882
Drug: Caffeine 200
Normalized name: caffeine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 200 mg BID
Study: 23660738
Drug: PDT delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDT delivered twice within 1 week (group A)
Study: 23660738
Drug: Sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham treatment without activating the laser (group C)
Study: 22545106
Drug: 1.7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 g of DHA and 0.6 g EPA daily for 6 months
Study: 7995008
Drug: Quinidine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinidine monotherapy
Study: 7995008
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of amiloride (1 mumol/L) and quinidine (10 mumol/L)
Study: 7995008
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment of amiloride and quinidine
Study: 2574728
Drug: Nifedipine twice
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine twice daily
Study: 2574728
Drug: Nisoldipine and
Normalized name: Nisoldipine
DrugBank: Nisoldipine (DB00401)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nisoldipine and Nifedipine combined with a beta-blocker
Study: 10792124
Drug: 10- to
Normalized name: tolnaftate 10 MG/ML [Blis-To-Sol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10- to 14-day therapies
Study: 10792124
Drug: 14-day therapies
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day therapies
Study: 10792124
Drug: 7-day therapies
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-day therapies
Study: 10792124
Drug: 10-day therapies
Normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day therapies
Study: 1530319
Drug: Intra-arterial infusion
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial infusion chemotherapy (I.A.)
Study: 1530319
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy (I.V.)
Study: 4018470
Drug: Isosorbide‐5‐mononitrate (IS‐5‐MN;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide‐5‐mononitrate (IS‐5‐MN; 40 mg orally)
Study: 4018470
Drug: Sustained-release Isosorbide
Normalized name: isosorbide Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release Isosorbide dinitrate (SRDI; 40 mg orally)
Study: 25748442
Drug: 5‐MTHF (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐MTHF (5 mM) administered locally via intradermal microdialysis in older adults.
Study: 25748442
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (5 mg/day) supplementation for 6 weeks in older adults.
Study: 23863960
Drug: CLEAR regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CLEAR regimen (oral levofloxacin, ethambutol, azithromycin, and rifampin)
Study: 15979246
Drug: Lifetime history
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lifetime history of drug treatment
Study: 15979246
Drug: No history
Approvals — FDA: no, EMA: no, PMDA: no
Description: No history of drug treatment
Study: 15979246
Drug: Craving drugs
Normalized name: BENZALKONIUM CHLORIDE 13 mg in 1 mL TOPICAL SPRAY [Skin Crave non-alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Craving drugs at least 15 days in the past month
Study: 8839602
Drug: Hypertensive, hypervolemic,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertensive, hypervolemic, hemodilutional therapy (HT)
Study: 1750429
Drug: Aluminum hydroxide-containing
Normalized name: Aluminum hydroxide-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide-containing antacid (113 mg per tablet, 2 tablets four times daily)
Study: 1750429
Drug: Aluminum hydroxide-containing
Normalized name: Aluminum hydroxide-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide-containing antacid
Study: 6976617
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (Aspirin), 3000 mg daily
Study: 6976617
Drug: Fluproquazone, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluproquazone, 300 mg daily
Study: 31537110
Drug: Nasalance-based preclassification
Normalized name: BAKING POWDER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasalance-based preclassification of oral-nasal balance disorders
Study: 31778601
Drug: esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: esomeprazole (40 mg/d)
Study: 31778601
Drug: famotidine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: famotidine (40 mg/d)
Study: 22588377
Drug: Coping Cat
Normalized name: cat hair extract
DrugBank: Felis catus hair (DB10499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coping Cat program (cognitive-behavioral therapy; CBT)
Study: 22092484
Drug: Vitamin trial
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin trial (Vitamin C = 500 mg/day + Vitamin E = 100 IU/day)
Study: 18852497
Drug: Monitoring as
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Monitoring as a form of therapy
Study: 3964334
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg t.i.d. indometacin
Study: 3964334
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg t.i.d. acemetacin
Study: 20082132
Drug: Multi-electrode array
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-electrode array ablation catheters with uninterrupted warfarin
Study: 20082132
Drug: Uninterrupted aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uninterrupted aspirin
Study: 18756743
Drug: Trimetazidine (Preductal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (Preductal MR) in addition to traditional therapy
Study: 11805921
Drug: Rofecoxib, 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib, 25 mg daily for 5 consecutive days starting 3 days before surgery
Study: 10715762
Drug: Lignocaine throat
Normalized name: Sucrets Sore Throat
DrugBank: Dyclonine (DB00645)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lignocaine throat spray only
Study: 8868980
Drug: Pimobendan 2.5
Normalized name: pimobendan 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pimobendan 2.5 mg daily
Study: 1595521
Drug: Trapidil (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trapidil (600 mg/day orally for 1 week before PTCA and for 4 to 6 months after PTCA)
Study: 1595521
Drug: Aspirin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (300 mg/day) and dipyridamole (150 mg/day)
Study: 6705164
Drug: Ketanserin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (2 mg/hr iv, preceded by a 10 mg bolus in three patients)
Study: 30145269
Drug: Remote delivery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote delivery (RD) using video conferencing on a tablet computer
Study: 26754679
Drug: Pomalidomide 4
Normalized name: pomalidomide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 4 mg
Study: 26754679
Drug: Pomalidomide 20
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide 20 mg
Study: 22475889
Drug: Lu AA21004
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AA21004 5 or 10 mg/day
Study: 22475889
Drug: Lu AA21004
Normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lu AA21004 5 or 10 mg/day (stable responders)
Study: 20444957
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol therapy
Study: 20444957
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol therapy in mice
Study: 16231850
Drug: Doxorubicin-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin-based chemotherapy
Study: 16231850
Drug: In-field radiation
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-field radiation therapy (RT)
Study: 16231850
Drug: Autologous stem
Normalized name: stem bromelain
DrugBank: Stem bromelain (DB12249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous stem cell transplantation and cisplatin- and MOPP-containing therapies
Study: 10071983
Drug: Etoposide (VP16)
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide (VP16) at various dose regimens (30 to 200 mg, infusion times 0.5 to 2 h)
Study: 7985891
Drug: Procollagen III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procollagen III levels of 1.75 U/mL or more on day 3
Study: 7985891
Drug: Procollagen III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procollagen III levels of 1.75 U/mL or more on day 7
Study: 7985891
Drug: Procollagen III
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procollagen III levels of 1.75 U/mL or more on day 14
Study: 1665493
Drug: AIO chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIO chemotherapy (A, 50 mg/m2 on day 1; I, 2 g/m2 on days 1-3; O, 2 mg on day 1) alternating with cisplatin (90 mg/m2 on day 1) and etoposide (150 mg/m2 on days 1-3)
Study: 1665493
Drug: AIO chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIO chemotherapy (A, Adriamycin 25 mg/m2 on days 1 + 2; I, ifosfamide 2 g/m2 on days 1-5; O, vincristine 2 mg on day 1)
Study: 6851037
Drug: i.v. atenolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. atenolol followed by oral treatment for 10 days
Study: 30926371
Drug: Walnut oral
Normalized name: Almond/Hazelnut/Pistachio/Walnut Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnut oral immunotherapy
Study: 24535791
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (levobupivacaine) with 20 mL 0.25% levobupivacaine and 40 mg methylprednisolone
Study: 24535791
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (bupivacaine) with 20 mL 0.25% bupivacaine and 40 mg methylprednisolone
Study: 24535791
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (control) with 20 mL physiological saline
Study: 22334121
Drug: Intravenous Δ⁹-THC
Normalized name: delta-9-THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Δ⁹-THC (0.015 mg/kg)
Study: 22334121
Drug: Intravenous Δ⁹-THC
Normalized name: delta-9-THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Δ⁹-THC (0.03 mg/kg)
Study: 17932908
Drug: Subcutaneous interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous interleukin-2 9 million IU daily
Study: 17932908
Drug: Cytokine treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine treatments (interferon-alfa and interleukin-2)
Study: 17932908
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate 200 mg daily
Study: 12414028
Drug: Intravenous crystalloid
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous crystalloid fluids
Study: 1983780
Drug: ICI 118,551
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI 118,551 (50 mg)
Study: 1983780
Drug: Diazepam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (2 mg)
Study: 7191779
Drug: Combination cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination cyclophosphamide, doxorubicin, and cis-dichlorodiammineplatinum(II) (CAP)
Study: 30343508
Drug: Tadalafil (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (40 mg, single daily dose)
Study: 30343508
Drug: Sildenafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (20 mg t.i.d.)
Study: 30343508
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (sildenafil and tadalafil)
Study: 17575230
Drug: Pemetrexed 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 600 mg/m2 (P600 arm)
Study: 17575230
Drug: Pemetrexed 900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed 900 mg/m2 (P900 arm)
Study: 9626829
Drug: Eptifibatide therapy
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide therapy (135-microg/kg bolus/0.5-microg/kg per min infusion or 135-microg/kg bolus/0.75-microg/kg per min infusion)
Study: 9626829
Drug: Placebo (placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (placebo bolus/placebo infusion)
Study: 9626829
Drug: PTCR within
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTCR within 24 h of thrombolytic therapy
Study: 9626829
Drug: Larger heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larger heparin doses during PTCR